This report analyzes the worldwide markets for Veterinary Vaccines in US$ Million by the following Product Segments – Companion Animal Vaccines (Canine Vaccines, & Feline Vaccines), and Livestock Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines, & Other Animal Vaccines). The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for each region for the period 2009 through 2017. A six-year historic analysis is also provided for these markets. The report profiles 69 companies including many key and niche players such as Bayer HealthCare AG, Biogenesis-Bago, Boehringer Ingelheim GmbH, Heska Corporation, Imugene Limited, Indian Immunologicals Ltd., Lohmann Animal Health, Merck & Co., Inc., Merck Animal Health, Merial Ltd., Pfizer, Inc., Pfizer Animal Health Global Poultry, Fort Dodge Animal Health, Protein Sciences Corporation, and Virbac Corporation. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-3
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
A. Companion Animal Vaccines I-4
B. Livestock Vaccines I-4
Porcine Vaccines I-4
Bovine Vaccines I-4
Poultry Vaccines I-4
Ovine Vaccines I-4
Equine Vaccines I-5
Other Animal Vaccines I-5


II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW & OUTLOOK II-1
Global Animal Health Care Industry – A Brief Review II-1
Table 1: Global Animal Health Products Market by Region
(2011): Percentage Share Breakdown by Value Sales for North
America, Europe, Latin America and Rest of World (includes
corresponding Graph/Chart) II-1

Table 2: Global Animal Health Products Market by Product
Group (2011): Percentage Share Breakdown by Value sales for
Parasiticides, Vaccines, Anti-Infectives, Medical Feed
Additives and Other Pharmaceuticals (includes corresponding
Graph/Chart) II-1
Animal Healthcare Market Grows Amidst Recession II-2
Veterinary Vaccines Industry Posts Moderate Growth II-2
Poultry Vaccines Industry: A Global Scenario II-2
Improved Manufacturing Techniques II-3
Improved Analysis II-3
Scope of the Report II-3

2. MARKET TRENDS & ISSUES II-4
Companion Animal Vaccines: Trailing on a High Growth Track II-4
OTC Market: A Potential Threat for Veterinarians II-4
Small Animal Practitioners Feel the Pinch of Recession II-4
Parasiticides, Systemic Agents To Drive The Market II-4
Taxonomy of Vaccines II-4
Bird Flu – The Aftermath II-5
Vaccination – Critical for Controlling Avian Influenza Virus II-5

3. PRODUCT OVERVIEW II-6
Vaccines – An Evolutionary Scan II-6
Contribution of Animal Research to Vaccine Production II-6
Veterinary Medicines- A Brief Review II-7
Preventive Medicines II-7
Therapeutic Medicines II-7
Others II-7
Development of Vaccines II-7
Production of Vaccines II-8
Veterinary Vaccines – An Essential Component of Animal Health
Care II-8
What Does A Veterinary Vaccine Do? II-9
Classification of Veterinary Vaccines II-9
Companion Animals Vaccines II-9
Canine Vaccines II-9
Feline Vaccines II-11
Livestock Vaccines II-12
Bovine Vaccines II-12
Poultry Vaccines II-13
Ovine Vaccines II-13
Porcine Vaccines II-14
Equine Vaccines II-14
Aquaculture Vaccines II-14
A Tabular Analysis on Select Animal Diseases Controlled by
Vaccines II-15
Vaccination and Its Reactions II-15
Veterinary Vaccines- Latest Breakthroughs II-15
Marker vaccines II-15
DNA vaccines II-15
Gene-deleted vaccines II-16
Viral-vectored vaccines II-16

4. NOTES ON SELECT ANIMAL DISEASES II-17
Brucellosis II-17
Tuberculosis II-17
Johne’s disease II-17
Spirochete Associated Diseases II-17
Respiratory Disease in Goats, Sheep, and Cattle II-18
Porcine Respiratory Diseases II-18
Mastitis II-18
African Swine Fever II-18
Avian Influenza II-19
East Coast Fever II-19
Hemorrhagic Septicemia II-19
Foot-And-Mouth Disease II-19
Japanese Encephalitis II-19
Rift Valley Fever II-20
Equine Virus II-20

5. PRODUCT INNOVATIONS/INTRODUCTIONS II-21
Intervet/Schering-Plough Animal Health Introduces a New Web
Site for Innovax recombinant Vaccines Product Line II-21
Pfizer Animal Health Introduces the First E. Coli Bacterial
Extract Vaccine II-21
Intervet Schering-Plough Animal Health Re-Launches EQUILIS®
StrepE for Horses II-21
Boehringer Ingelheim Vetmedica Launches Single Shot 3FLEX
combination package PL II-21
Pfizer Animal Health Launches INFORCE™ 3 II-21
Boehringer Ingelheim Introduces Ingelvac CircoFLEX® in Russia II-22
Pfizer Animal Health Introduces Bopriva® for Bull and Beef
Market in NZ II-22
GALVmed, Inter-African Bureau for Animal Resources Launch ECF
Vaccine II-22
BIVI launches Five New Variants of Vetera® Vaccines II-23
Hipra Announces Launch of Suiseng® II-23
Aceto Corporation Receives Approval to Sell Suppliera[euro]™
in the US II-23
Intervet Schering-Plough Unleashes NOBIVAC Lyme Vaccine for Dogs II-24
Intervet Schering-Plough Animal Health Introduces PORCILIS PCV
Vaccine II-24
Lohmann Launches AviPro® MEGAN®VAC Vaccination for Salmonella
Disease II-24
Intervet Schering Plough Animal Health Introduces Circovirosis
Vaccine II-24
Pfizer Animal Health Develops Inovocox® Vaccine II-24
Intervet/Schering-Plough Animal Health Launches Bravoxin 10 II-25
Bioject and Merial Rolls Out Derma-Vac NF II-25
Defra to Launch Bovine Tuberculosis Vaccine II-25

6. PRODUCT INTRODUCTIONS/INNOVATIONS – A HISTORIC PERSPECTIVE BUILDER II-26
Intervet International Develops Bluetongue Vaccine II-26
Hester Biosciences Unveils Anti-Coryza Vaccine II-26
Intervet/Schering-Plough Animal Health Introduces Bovilis BTV8
Vaccine II-26
Tecnovax Develops Vaccine for Salmon Virus II-26
Tamil Nadu Veterinary and Animal Science University and The
Indian Veterinary Research Institute Develop Vaccine II-26
Lohmann Animal Health Develops AviPro IBD Xtreme II-26
Intervet/Schering-Plough Animal Health Launches EquiRab™ II-27
Lohmann Animal Health Introduces Larger Doses of AviPro®
ViBursa CE II-27
Lohmann Animal Health International Rolls Out AviBlue II-27
Fort Dodge Animal Health Unveils West Nile-Innovator DNA II-28
Univet Agricultural Products Introduces Coglapest II-28
Intervet/Schering-Plough Animal Health Launches Porcilis® COLI 6C II-28
Pfizer Animal Health Unveils FluSure® XP Defense System II-28
Pfizer Animal Health Launches Improvac® II-29
Intervet/Schering-Plough Animal Health Develops Onset™ 5
Intranasal (IN) Vaccine II-29
Merial Rolls Out BTVPUR AlSap 8 II-29
Pfizer Animal Health Introduces FarrowSure® GOLD and
FarrowSure® GOLD B II-30
Schering-Plough Animal Health Unveils CAVALRY 9 II-30
Lohmann Animal Health Develops BTO2 REO Vaccine II-30
Agroinsuvet Introduces New Vaccines II-31
Merial Rolls Out Vaxxitek® HVT+IBD Hatchery Vaccine for
Poultry Industry II-31
Intervet & Friedrich-Loeffler-Institute Develop Dual Vaccine
Prototype for Birds II-31
Schering-Plough Receives USDA License for its Rhusigen™
Erysipelas Vaccine II-31
USDA Approves Use of PreveNile™ Vaccine for Horses II-32
Fort Dodge Animal Health Develops Reverse Genetics Avian Vaccine II-32
Boehringer Ingelheim’s Swine Vaccine Gains Approval in Australia II-32
Merial Limited Gets USDA Approval for DNA Vaccine for Melanoma
in Dogs II-32
Embrex’s Poultry Vaccine Inovocox Gets USDA Approval II-33
Skystar Bio-Pharmaceutical Develops Avian Influenza Vaccine II-33
United States Department of Agriculture Grants Conditional
License for Necrotic Enteritis Vaccine II-33
Fort Dodge Receives USDA License for Pyramid®10 II-33
USDA Licenses Use of Fort Dodge’s Suvaxyn® PCV2 Vaccine in Pigs II-34
USDA Grants Conditional License to Pfizer’s New Canine Vaccine II-34

7. RECENT INDUSTRY ACTIVITY II-35
Pfizer to Restructure Indian Animal Health Unit II-35
Pfizer Poultry Health Acquires Alpharma II-35
Intervet/Schering-Plough Animal Health Becomes Merck Animal
Health II-35
Centegen Enters into Licensing Partnership with Merial II-35
The Ugandan Government Enters into Partnership with Brentec
Vaccines International II-36
Pfizer Animal Health Kicks Off Equine Business Unit II-36
Pfizer Animal Health Acquires Microtek II-36
GenVec Enters into Collaboration with Merial to Develop and
Commercialize FMD Vaccine II-36
Pfizer Animal Health Inks Global Licensing Deal with Epitopix II-37
Indian Immunologicals Intends to Establish a New Facility in
Hyderabad II-37
Pfizer Phases out Animal Vaccine Manufacturing Unit of Wyeth
in the Netherlands II-37
Vivalis Signs Commercial License for EB66® Cell Line Platform II-37
Ibio Grants Rights of iBioLaunch platform to Government Funded
Project II-37
Intervet/Schering-Plough Animal Health Unveils Production
Center at Boxmeer II-38
Globion India Announced Plans to Develop Eight New Vaccines II-38
Veterinary Services Department Intends to Upgrade VRI II-38
VIVALIS Grants Rights of EB66® Cell Line To KYOTO BIKEN II-38
Vical Enters Into Agreement with GenomIdea for Development of
DNA Vaccine II-38
Intervet/Schering-Plough Animal Health Unveils the New Freeze
-drying and Specialized Central Filling Unit II-39
Him Electronics Enters into Partnership with Hester Bioscience
to Produce Animal Vaccines II-39
Intervet/Schering-Plough Animal Health Receives Approval for
Nobivac Lepto4 II-40
Biolex Enters into Collaboration With Merial for Research and
Development II-40
Intervet/Schering-Plough Animal Health Receives Full License
from USDA for Nobivac® Vaccine II-40
Intercell Inks License Agreement with Boehringer II-41
Intervet/Schering-Plough Recalls PreveNile West Nile Virus
Vaccine in the US II-41
Merial Gains Full License of ONCEPT™ from USDA II-41
Virbac Acquires Veterinary Assets from Pfizer II-41
Harbin Pharmaceutical Group Holding Acquires Animal Vaccine
Business From Pfizer II-41
Boehringer Ingelheim Acquires Certain Cattle Vaccines from
Fort Dodge II-41
Virbac Acquires 30% Share in Santa Elena II-42
Merck and Sanofi-Aventis to Merge their Animal Health Business II-42
Elanco to Take Over Pfizer’s Animal Health Products Portfolio II-42
Boehringer Ingelhei to Acquire Pfizer’s Fort Dodge Animal
Health Unit II-42
ImmunoVaccine Inks Deal with Pfizer II-43
Merck Merges with Schering-Plough II-43
Pfizer Acquires Wyeth II-43
Merial Receives Marketing License for BTVPUR AlSap 8 Vaccine II-44
Epitopix Obtains Approval to Sell Siderophore Receptor and
Porin Vaccine II-44
Phibro Animal Health Acquires Animal Health Division of Abic II-44
Fort Dodge Animal Health and Vivalis Sign Commercial License Deal II-45
Hester Biosciences Expands Gujarat Based Facility II-45
Intervet/Schering-Plough Animal Health Replaces Bovilis® IBR
Vaccine with Bovilis® IBR Marker Live II-45
Tangshan Yian Biological Engineering Wins Approval from
Ministry of Agriculture of China II-45
Lohmann Animal Health International Signs an Agreement with
Celldex Therapeutics II-46
Intervet/Schering-Plough Animal Health Starts New
Manufacturing Facility II-46
Laprovet Commences New Facility II-46
ImmunoVaccine Technologies and La Jolla Institute for Allergy
& Immunology Enter into an Agreement II-46
Merial Signs a Toll Distribution and Manufacturing Agreement
with Newport Laboratories II-47
BOEHRINGER INGELHEIM Animal Health Signs Research License Deal
with Vivalis II-47
AviTech Selects Merial as a Distributor and Service Provider II-47

8. STRATEGIC CORPORATE DEVELOPMENTS – A HISTORIC PERSPECTIVE BUILDER II-48
Bayer Inks Agreement with Juvaris II-48
Pfizer Inks Agreement with ImmunoVaccine Technologies II-48
BioVet Inaugurates BSL-4 Production Unit in India II-48
Vaxine to Take over Protein Sciences II-48
Pfizer Inaugurates a New Development Facility for Veterinary
Vaccines II-48
Merial to Establish Animal Vaccine Manufacturing Plant II-49
BNC Bioniche Life Sciences Bags Approval to Sell Econiche
Vaccines II-49
Hind Bio-Pharmaceuticals to Establish Animal Vaccines Division II-49
Pfizer’s Animal Health Unit Acquires Schering-Plough’s Product
License in Europe II-49
Grupo Mathiesen Takes Over Centro de Diagnostico Veterinario II-50
Harbin Veterinary Research Institute Opens Animal Vaccine
Manufacturing Base II-50
Bioject Medical Technologies Enters into a Long-Term Supply,
Development and License Contract with Merial II-50
Vivalis SA Signs Letter of Intent with Intervet/ Schering-Plough II-50
Biochemiq Enters into Partnership with Labovet II-51
Microbix Biosystems Purchases Production Plant II-51
Beijing Veterinary Biological Product Factory Starts Operation
in New Plant II-51
Changzhou Tongtai Biopharmaceutical Sets Up Rabies Vaccine
Facility II-51
Schering-Plough to Sell Health Products of Animals to Pfizer
and Virbac II-51
Pfizer Group Establishes a Veterinary Vaccines Development Center II-52
Phylaxia to Acquire Gazdasagi Radio and Kozep-europai
Gazterminal Zrt II-52
Bayer HealthCare AG’s Animal Health Unit Enters into Licensing
Agreement with Juvaris BioTherapeutics II-52
Vivalis Enters into a Commercial License Contract with Virbac II-52
ImmunoVaccine Technologies Signs Licensing Agreement with
Pfizer Animal Health II-52
Kaketsuken and Vivalis Extends Research Collaboration II-53
Heska Amends Distribution Contract with Agri Laboratories II-53
Prevtec Microbia and Saskatchewan Research Council Receives
Approval to Market and Manufacture Coliprotec II-53
Imugene and Merial Enter into an Agreement II-53
Celldex Therapeutics Merges with AVANT Immunotherapeutics’
Subsidiary II-54
Ceva Sante Animale Acquires Delvet II-54
Inovio Biomedical Signs Merger Agreement with VGX Pharmaceuticals II-54
Environmental Risk Management Authority Approves equine
Influenza Vaccine II-54
Functional Technologies Commences Operations of Phyterra Bio II-55
Summit VetPharm Enters into Distribution Partnership with
Webster Veterinary Unit II-55
PerOs Receives Establishment and Bacterin License from USDA II-55
Wyeth’s Fort Dodge Animal Health Unit Acquires Poultry Vaccines II-55
Boehringer Ingelheim Vetmedica Receives Approval for Express®
FP and Express® Vaccines from the USDA II-56
Merial Bags Major Australian Contract II-56
United States Department of Agriculture Approves Intervet Vaccine II-56
Merial Pockets Ancare II-56
Heska Revises Distribution Agreement with AgriLabs II-57
Animal Health International Acquires Kane Veterinary Supplies II-57
Industrial Equity Investments Pockets Arysta LifeScience II-57
Henry Schein Acquires W&J Dunlop II-57
Tecnovax Establishes New Facility II-57
Pingtung Agricultural to Set Up an Exclusive Veterinary Park II-58
Ouro Fino To Expand Veterinary Product Suite II-58
Alpharma Acquires Yantai Jinhai II-58
Pfizer Animal Health Acquires Embrex II-58
Schering-Plough Acquires Intervet II-58
Schering-Plough Acquires Organon BioSciences II-59
Intervet Sets Up New Animal Vaccine Production Facility in
Boxmeer II-59
Crucell Licenses PER.C6® Technology to Pfizer Animal Health II-59
Central Veterinary Research Laboratory to Synthesize New
Animal Vaccines II-59
Pfizer to Shut Down Omaha Animal Vaccine Center II-60
IGI Licenses Novasomes to Novavax II-60
Bogor Agricultural Institute Collaborates with Shigeta Animal
Pharmaceuticals II-60
Suguna Poultry Steps into Livestock Vaccine Production Business II-61
European Medicines Agency Grants Community Authorization for
Nobilis Influenza H7N1 II-61
AVANT Immunotherapeutics & Pfizer Collaborate to Develop
Animal Vaccines II-61
Intervet International Acquires FMD Vaccine Production
Facility from Bayer Healthcare II-61
Canadian Food Inspection Agency Authorizes Bioniche E. Coli
O157:H7 Cattle Vaccine for Field Use II-62
Hemispherx Biopharma Acquires DOGS Molecule Patent II-62
Hind Industries to Establish Animal Vaccine Formulations Plant
at Patiala II-62
Cryosite and Animal Health Australia Form Partnership II-62
Hester Pharmaceuticals Plans Capacity Expansion II-62
Biovet to Set up Animal Vaccine Plant in Karnataka II-63
Bogor Institute of Agricultureand Shigeta Establish JV for
Production of CLOSE 5.1 Vaccine II-63
IPB Shigeta Acquires Bird Flu Vaccine Rights from MedImmune II-63
Bioject Medical Technologies Signs Three Agreements WithMerial II-63
PetCARE Television Network signs Distribution Agreement with
Butler Animal Health Supply II-63
Poultry Vaccine to be produced in Vladimir II-64

9. FOCUS ON SELECT GLOBAL PLAYERS II-65
Bayer HealthCare AG (Germany) II-65
Biogenesis-Bago (Argentina) II-65
Boehringer Ingelheim GmbH (Germany) II-65
Heska Corporation (US) II-66
Imugene Limited (Australia) II-66
Indian Immunologicals Ltd (India) II-66
Lohmann Animal Health (US) II-67
Merck & Co., Inc. (US) II-67
Merck Animal Health II-68
Merial Ltd. (US) II-68
Pfizer, Inc. (US) II-68
Pfizer Animal Health Global Poultry II-69
Fort Dodge Animal Health (US) II-69
Protein Sciences Corporation (US) II-69
Virbac Corporation (US) II-70

10. GLOBAL MARKET PERSPECTIVE II-71
Table 3: World Recent Past, Current & Future Analysis for
Veterinary Vaccines by Geographic Region – US, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-71

Table 4: World Historic Review Veterinary Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-72

Table 5: World 15-Year Perspective for Veterinary Vaccines by
Geographic Region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017(includes corresponding Graph/Chart) II-73

Table 6: World Recent Past, Current & Future Analysis for
Companion Animal Vaccines by Geographic Region – US, Europe
and Rest of World Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-74

Table 7: World Historic Review for Companion Animal Vaccines
by Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-75

Table 8: World 15-Year Perspective for Companion Animal
Vaccines by Geographic Region – Percentage Breakdown of Dollar
Sales for US, Europe and Rest of World Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) II-76

Table 9: World Recent Past, Current & Future Analysis for
Companion Animal Vaccines by Product Segment- Canine Vaccines
& Feline Vaccines Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) II-77

Table 10: World Historic Review for Companion Animal Vaccines
by Product Segment- Canine Vaccines & Feline Vaccines Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-78

Table 11: World 15-Year Perspective for Companion Animal
Vaccines by Product Segment – Percentage Breakdown of Dollar
Sales for Canine Vaccines & Feline Vaccines Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) II-79

Table 12: World Recent Past, Current & Future Analysis for
Canine Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-80

Table 13: World Historic Review for Canine Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-81

Table 14: World 15-Year Perspective for Canine Vaccines by
Geographic region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-82

Table 15: World Recent Past, Current & Future Analysis for
Feline Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-83

Table 16: World Historic Review for Feline Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-84

Table 17: World 15-Year Perspective for Feline Vaccines by
Geographic Region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017(includes corresponding Graph/Chart) II-85

Table 18: World Recent Past, Current & Future Analysis for
Livestock Vaccines by Geographic Region – US, Europe and Rest
of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-86

Table 19: World Historic Review for Livestock Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-87

Table 20: World 15-Year Perspective for Livestock Vaccines by
Geographic Region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-88

Table 21: World Recent Past, Current & Future Analysis for
Livestock Vaccines by Product Segment – Porcine Vaccines,
Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine
Vaccines and Other Animal Vaccines Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) II-89

Table 22: World Historic Review for Livestock Vaccines by
Product Segment – Porcine Vaccines, Bovine Vaccines, Poultry
Vaccines, Ovine Vaccines, Equine Vaccines & Other Animal
Vaccines Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) II-90

Table 23: World 15-Year Perspective for Livestock Vaccines by
Product Segment – Percentage Breakdown of Dollar Sales for
Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, Equine Vaccines & Other Animal Vaccines Markets for
Years 2003, 2011 & 2017 (includes corresponding Graph/Chart) II-91

Table 24: World Recent Past, Current & Future Analysis for
Porcine Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-92

Table 25: World Historic Review for Porcine Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-93

Table 26: World 15-Year Perspective for Porcine Vaccines by
Geographic Region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-94

Table 27: World Recent Past, Current and Future Analysis for
Bovine Vaccines by Geographic Region – US, Europe & Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-95

Table 28: World Historic Review for Bovine Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-96

Table 29: World 15-Year Perspective for Bovine Vaccines by
Geographic region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017(includes corresponding Graph/Chart) II-97

Table 30: World Recent Past, Current & Future Analysis for
Poultry Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-98

Table 31: World Historic Review for Poultry Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-99

Table 32: World 15-Year Perspective for Poultry Vaccines by
Geographic region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-100

Table 33: World Recent Past, Current & Future Analysis for
Ovine Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-101

Table 34: World Historic Review for Ovine Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-102

Table 35: World 15-Year Perspective for Ovine Vaccines by
Geographic region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017(includes corresponding Graph/Chart) II-103

Table 36: World Recent Past, Current & Future Analysis for
Equine Vaccines by Geographic Region – US, Europe and Rest of
World Markets Independently Analyzed with Annual Sales Figures
in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-104

Table 37: World Historic Review for Equine Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-105

Table 38: World 15-Year Perspective for Equine Vaccines by
Geographic region – Percentage Breakdown of Dollar Sales for
US, Europe and Rest of World Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) II-106

Table 39: World Recent Past, Current & Future Analysis for
Other Animal Vaccines by Geographic Region – US, Europe and
Rest of World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) II-107

Table 40: World Historic Review for Other Animal Vaccines by
Geographic Region – US, Europe and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) II-108

Table 41: World 15-Year Perspective for Other Animal Vaccines
by Geographic region – Percentage Breakdown of Dollar Sales
for US, Europe and Rest of World Markets for Years 2003, 2011
& 2017 (includes corresponding Graph/Chart) II-109


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
H5N1 Virus: A Conundrum for the US Industry III-1
Rabies Cases in the US III-1
B.Market Analytics III-2
Table 42: US Recent Past, Current & Future Analysis for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines, Equine Vaccines and Other
Animal Vaccines) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-2

Table 43: US Historic Review for Veterinary Vaccines by
Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, Equine Vaccines and Other Animal Vaccines) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-3

Table 44: US 15-Year Perspective for Veterinary Vaccines by
Product Group/Segment – Percentage Breakdown of Dollar Sales
for Companion Animal Vaccines (Canine Vaccines and Feline
Vaccines) and Livestock Vaccines (Porcine Vaccines, Bovine
Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines
and Other Animal Vaccines) Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) III-4

2. EUROPE III-5
Market Analysis III-5
Table 45: European Recent Past, Current & Future Analysis
for Veterinary Vaccines by Geographic Region – France,
Germany, Italy, UK and Rest of Europe Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2009 through 2017 (includes corresponding Graph/Chart) III-5

Table 46: European Historic Review for Veterinary Vaccines
by Geographic Region – France, Germany, Italy, UK and Rest
of Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-6

Table 47: European 15-Year Perspective for Veterinary
Vaccines by Geographic Region – Percentage Breakdown of
Dollar Sales for France, Germany, Italy, UK and Rest of
Europe for Years 2003, 2011 & 2017 (includes corresponding
Graph/Chart) III-7

Table 48: European Recent Past, Current & Future for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines, Equine Vaccines and Other
Animal Vaccines) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-8

Table 49: European Historic Review for Veterinary Vaccines
by Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, Equine Vaccines and Other Animal Vaccines) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-9

Table 50: European 15-Year Perspective for Veterinary
Vaccines by Product Group/Segment – Percentage Breakdown of
Dollar Sales for Companion Animal Vaccines (Canine Vaccines
and Feline Vaccines) and Livestock Vaccines (Porcine
Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines,
Equine Vaccines and Other Animal Vaccines) Markets for Years
2003, 2011 & 2017(includes corresponding Graph/Chart) III-10

2a. FRANCE III-11
Market Analytics III-11
Table 51: French Recent Past, Current & Future Analysis for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines and Equine Vaccines)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-11

Table 52: French Historic Review for Veterinary Vaccines by
Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, and Equine Vaccines) Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2003 through 2008 (includes corresponding Graph/Chart) III-12

Table 53: French 15-Year Perspective for Veterinary Vaccines
by Product Group/Segment – Percentage Breakdown of Dollar
Sales for Companion Animal Vaccines (Canine Vaccines and
Feline Vaccines) and Livestock Vaccines (Porcine Vaccines,
Bovine Vaccines, Poultry Vaccines, Ovine Vaccines and Equine
Vaccines) Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-13

2b. GERMANY III-14
Market Analytics III-14
Table 54: German Recent Past, Current & Future Analysis for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines and Equine Vaccines)
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2009 through 2017 (includes
corresponding Graph/Chart) III-14

Table 55: German Historic Review for Veterinary Vaccines by
Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines and Equine Vaccines) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2003
through 2008 (includes corresponding Graph/Chart) III-15

Table 56: German 15-Year Perspective for Veterinary Vaccines
by Product Group/ Segment – Percentage Breakdown of Dollar
Sales for Companion Animal Vaccines (Canine Vaccines and
Feline Vaccines) and Livestock Vaccines (Porcine Vaccines,
Bovine Vaccines, Poultry Vaccines, Ovine Vaccines and Equine
Vaccines) Markets for Years 2003, 2011 & 2017 (includes
corresponding Graph/Chart) III-16

2c. ITALY III-17
Market Analytics III-17
Table 57: Italian Recent Past, Current & Future Analysis for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines, Equine Vaccines and Other
Animal Vaccines) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-17

Table 58: Italian Historic Review for Veterinary Vaccines by
Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, Equine Vaccines and Other Animal Vaccines) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-18

Table 59: Italian 15-Year Perspective for Veterinary
Vaccines by Product Group/Segment – Percentage Breakdown of
Dollar Sales for Companion Animal Vaccines (Canine Vaccines
and Feline Vaccines) and Livestock Vaccines (Porcine
Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines,
Equine Vaccines and Other Animal Vaccines) Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) III-19

2d. THE UNITED KINGDOM III-20
Market Analytics III-20
Table 60: UK Recent Past, Current & Future Analysis for
Veterinary Vaccines by Product Group/Segment – Companion
Animal Vaccines (Canine Vaccines and Feline Vaccines) and
Livestock Vaccines (Porcine Vaccines, Bovine Vaccines,
Poultry Vaccines, Ovine Vaccines, Equine Vaccines and Other
Animal Vaccines) Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2009 through 2017
(includes corresponding Graph/Chart) III-20

Table 61: UK Historic Review for Veterinary Vaccines by
Product Group/Segment – Companion Animal Vaccines (Canine
Vaccines and Feline Vaccines) and Livestock Vaccines
(Porcine Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine
Vaccines, Equine Vaccines and Other Animal Vaccines) Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2003 through 2008 (includes corresponding
Graph/Chart) III-21

Table 62: UK 15-Year Perspective for Veterinary Vaccines by
Product Group/Segment – Percentage Breakdown of Dollar Sales
for Companion Animal Vaccines (Canine Vaccines and Feline
Vaccines) and Livestock Vaccines (Porcine Vaccines, Bovine
Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines
and Other Animal Vaccines) Markets for Years 2003, 2011 &
2017 (includes corresponding Graph/Chart) III-22

2e. REST OF EUROPE III-23
A.Market Analysis III-23
A Note on Danish Veterinary Services III-23
The 2002 Standards of Danish Medicines recommends test for
antibody inducing fragments in veterinary vaccines III-23
Hungary Vaccinates Birds Across Zoos III-24
Russia Mass-Produces Vaccines Against Avian Flu III-24
B.Market Analytics III-25
Table 63: Rest of Europe Recent Past, Current & Future
Analysis for Veterinary Vaccines – by Product Group/ Segment
for Companion Animal Vaccines (Canine Vaccines and Feline
Vaccines) and Livestock Vaccines (Porcine Vaccines, Bovine
Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines
and Other Animal Vaccines) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) III-25

Table 64: Rest of Europe Historic Review for Veterinary
Vaccines by Product Group/Segment – Companion Animal
Vaccines (Canine Vaccines and Feline Vaccines) and Livestock
Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry
Vaccines, Ovine Vaccines, Equine Vaccines and Other Animal
Vaccines) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-26

Table 65: Rest of Europe 15-Year Perspective for Veterinary
Vaccines by Product/Segment – Percentage Breakdown of Dollar
Sales for Companion Animal Vaccines (Canine Vaccines and
Feline Vaccines) and Livestock Vaccines (Porcine Vaccines,
Bovine Vaccines, Poultry Vaccines, Ovine Vaccines, Equine
Vaccines and Other Animal Vaccines) Markets for Years 2003,
2011 & 2017 (includes corresponding Graph/Chart) III-27

3. REST OF WORLD III-28
A.Market Analysis III-28
Focus on Select Regions III-28
Canada III-28
Overview of Canadian Animal Health Industry III-28
Import and Manufacture of Veterinary Biologics III-28
First to Access E. coli 0157:H7 Vaccine III-28
China III-29
A Glance at the Animal Vaccine Market in China III-29
China Initiates Mass Vaccination Campaign Against Bird Flu
Virus III-29
Australia III-30
A Note on Australian Veterinary Therapeutics Market III-30
India III-30
ICAR Develops Indigenous Bird Flu Vaccine III-30
Thailand III-30
Japan & Thailand to Cooperate for Developing Bird Flu Vaccine III-30
Taiwan III-31
Taiwan’s Animal Healthcare Industry Under Scan III-31
Malaysia III-31
Malaysia Initiates Measures to Deal with Potential Flu
Pandemic III-31
Kazakhstan III-31
Kazakhstan Takes Proactive Measures Against Bird Flu III-31
North Korea III-31
North Korea Develops Bird Flu Vaccine III-31
Vietnam III-32
Vietnam Imports Bird Flu Vaccines III-32
Egypt III-32
Egypt Reports H5N1 Infection in Vaccinated Flocks III-32
Kenya III-32
Kenya Mass-Manufactures Vaccines Against Rift Valley Fever III-32
B.Market Analytics III-33
Table 66: Rest of World Recent Past, Current & Future
Analysis for Veterinary Vaccines – by Product Group/ Segment
for Companion Animal Vaccines (Canine Vaccines and Feline
Vaccines) and Livestock Vaccines (Porcine Vaccines, Bovine
Vaccines, Poultry Vaccines, Ovine Vaccines, Equine Vaccines
and Other Animal Vaccines) Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2009
through 2017 (includes corresponding Graph/Chart) III-33

Table 67: Rest of World Historic Review for Veterinary
Vaccines by Product Group/Segment – Companion Animal
Vaccines (Canine Vaccines and Feline Vaccines) and Livestock
Vaccines (Porcine Vaccines, Bovine Vaccines, Poultry
Vaccines, Ovine Vaccines, Equine Vaccines and Other Animal
Vaccines) Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2003 through 2008 (includes
corresponding Graph/Chart) III-34

Table 68: Rest of World 15-Year Perspective for Veterinary
Vaccines by Product Group/Segment – Percentage Breakdown of
Dollar Sales for Companion Animal Vaccines (Canine Vaccines
and Feline Vaccines) and Livestock Vaccines (Porcine
Vaccines, Bovine Vaccines, Poultry Vaccines, Ovine Vaccines,
Equine Vaccines and Other Animal Vaccines) Markets for Years
2003, 2011 & 2017 (includes corresponding Graph/Chart) III-35


IV. COMPETITIVE LANDSCAPE


Total Companies Profiled: 69 (including Divisions/Subsidiaries – 97)

——————————————
Region/Country Players
——————————————
The United States 30
Canada 5
Japan 3
Europe 28
France 3
Germany 8
The United Kingdom 1
Italy 2
Rest of Europe 14
Asia-Pacific (Excluding Japan) 22
Latin America 5
Africa 1
Middle-East 3